Coloplast A/S (CLPBF)
USD 112.54
(0.0%)
USD 112.54
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 18.65 Billion DKK | 1.98% |
| 2022 | 18.29 Billion DKK | 682.46% |
| 2021 | 2.33 Billion DKK | 64.19% |
| 2020 | 1.42 Billion DKK | 67.14% |
| 2019 | 852 Million DKK | -19.92% |
| 2018 | 1.06 Billion DKK | -6.83% |
| 2017 | 1.14 Billion DKK | 452.47% |
| 2016 | -324 Million DKK | 58.51% |
| 2015 | -781 Million DKK | 11.15% |
| 2014 | -879 Million DKK | 36.9% |
| 2013 | -1.39 Billion DKK | -105.76% |
| 2012 | -677 Million DKK | -187.24% |
| 2011 | 776 Million DKK | 356.11% |
| 2010 | -303 Million DKK | -116.29% |
| 2009 | 1.86 Billion DKK | -39.55% |
| 2008 | 3.07 Billion DKK | 8.96% |
| 2007 | 2.82 Billion DKK | -0.6% |
| 2006 | 2.84 Billion DKK | 306.44% |
| 2005 | 699 Million DKK | 194.88% |
| 2004 | -736.71 Million DKK | -143.9% |
| 2003 | 1.67 Billion DKK | 14.07% |
| 2002 | 1.47 Billion DKK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 23.62 Billion DKK | 14.03% |
| 2024 Q1 | 20.71 Billion DKK | 11.03% |
| 2024 Q3 | 18.63 Billion DKK | -21.1% |
| 2023 Q3 | 21.26 Billion DKK | 1.14% |
| 2023 Q1 | 21.52 Billion DKK | 17.65% |
| 2023 FY | 18.65 Billion DKK | 1.98% |
| 2023 Q4 | 18.65 Billion DKK | -12.25% |
| 2023 Q2 | 21.02 Billion DKK | -2.33% |
| 2022 Q2 | 20.56 Billion DKK | 368.07% |
| 2022 Q1 | 4.39 Billion DKK | 87.94% |
| 2022 FY | 18.29 Billion DKK | 682.46% |
| 2022 Q3 | 19.96 Billion DKK | -2.95% |
| 2022 Q4 | 18.29 Billion DKK | -8.35% |
| 2021 Q1 | 4.23 Billion DKK | 197.05% |
| 2021 FY | 2.33 Billion DKK | 64.19% |
| 2021 Q4 | 2.33 Billion DKK | -39.02% |
| 2021 Q3 | 3.83 Billion DKK | 3.43% |
| 2021 Q2 | 3.7 Billion DKK | -12.36% |
| 2020 Q4 | 1.42 Billion DKK | -46.06% |
| 2020 Q1 | 3.05 Billion DKK | 258.92% |
| 2020 Q2 | 2.67 Billion DKK | -12.66% |
| 2020 Q3 | 2.64 Billion DKK | -1.16% |
| 2020 FY | 1.42 Billion DKK | 67.14% |
| 2019 Q1 | 2.7 Billion DKK | 154.23% |
| 2019 FY | 852 Million DKK | -19.92% |
| 2019 Q3 | 2.48 Billion DKK | 5.07% |
| 2019 Q4 | 852 Million DKK | -65.76% |
| 2019 Q2 | 2.36 Billion DKK | -12.46% |
| 2018 Q3 | 2.62 Billion DKK | -2.02% |
| 2018 Q1 | 2.39 Billion DKK | 109.28% |
| 2018 Q4 | 1.06 Billion DKK | -59.42% |
| 2018 Q2 | 2.67 Billion DKK | 11.97% |
| 2018 FY | 1.06 Billion DKK | -6.83% |
| 2017 Q3 | 2.23 Billion DKK | 0.59% |
| 2017 Q2 | 2.22 Billion DKK | -4.93% |
| 2017 Q1 | 2.33 Billion DKK | 820.68% |
| 2017 Q4 | 1.14 Billion DKK | -48.86% |
| 2017 FY | 1.14 Billion DKK | 452.47% |
| 2016 Q4 | -324 Million DKK | -164.93% |
| 2016 Q2 | -377 Million DKK | -1695.24% |
| 2016 FY | -324 Million DKK | 58.51% |
| 2016 Q3 | 499 Million DKK | 232.36% |
| 2016 Q1 | -21 Million DKK | 97.31% |
| 2015 FY | -781 Million DKK | 11.15% |
| 2015 Q2 | -189 Million DKK | -209.84% |
| 2015 Q1 | -61 Million DKK | 93.06% |
| 2015 Q3 | 135 Million DKK | 171.43% |
| 2015 Q4 | -781 Million DKK | -678.52% |
| 2014 Q2 | -324 Million DKK | 2.7% |
| 2014 Q4 | -879 Million DKK | -251.6% |
| 2014 FY | -879 Million DKK | 36.9% |
| 2014 Q1 | -333 Million DKK | 76.09% |
| 2014 Q3 | -250 Million DKK | 22.84% |
| 2013 Q3 | -471 Million DKK | -344.34% |
| 2013 FY | -1.39 Billion DKK | -105.76% |
| 2013 Q4 | -1.39 Billion DKK | -195.75% |
| 2013 Q2 | -106 Million DKK | -130.55% |
| 2013 Q1 | 347 Million DKK | 151.26% |
| 2012 Q3 | 221 Million DKK | -45.83% |
| 2012 Q4 | -677 Million DKK | -406.33% |
| 2012 FY | -677 Million DKK | -187.24% |
| 2012 Q1 | 1.24 Billion DKK | 60.57% |
| 2012 Q2 | 408 Million DKK | -67.26% |
| 2011 Q3 | 1.59 Billion DKK | -8.52% |
| 2011 FY | 776 Million DKK | 356.11% |
| 2011 Q1 | 1.87 Billion DKK | 720.13% |
| 2011 Q2 | 1.73 Billion DKK | -7.5% |
| 2011 Q4 | 776 Million DKK | -51.19% |
| 2010 Q3 | 1.9 Billion DKK | -2.76% |
| 2010 Q4 | -303 Million DKK | -115.93% |
| 2010 FY | -303 Million DKK | -116.29% |
| 2010 Q2 | 1.95 Billion DKK | -2.1% |
| 2010 Q1 | 1.99 Billion DKK | 7.42% |
| 2009 FY | 1.86 Billion DKK | -39.55% |
| 2009 Q4 | 1.86 Billion DKK | 0.0% |
| 2008 FY | 3.07 Billion DKK | 8.96% |
| 2007 FY | 2.82 Billion DKK | -0.6% |
| 2006 FY | 2.84 Billion DKK | 306.44% |
| 2005 FY | 699 Million DKK | 194.88% |
| 2004 FY | -736.71 Million DKK | -143.9% |
| 2003 FY | 1.67 Billion DKK | 14.07% |
| 2002 FY | 1.47 Billion DKK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Medical Technologies Inc. | 479.63 Thousand USD | -3889556.84% |
| Ansell Limited | -54.99 Million USD | 34021.93% |
| Ansell Limited | -55.1 Million USD | 33958.439% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | -36.49 Million USD | 51221.9% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | -105.1 Thousand USD | 17750475.825% |
| Psykey, Inc. | 634.59 Thousand USD | -2939737.029% |
| ConvaTec Group Plc | 1.2 Billion USD | -1453.887% |
| ConvaTec Group Plc | 1.2 Billion USD | -1451.693% |
| Encision Inc. | 1.29 Million USD | -1445325.055% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | 2.3 Million USD | -807967.858% |
| Innovative MedTech Inc. | 1.76 Million USD | -1057055.291% |
| LifePoint, Inc. | -3.26 Million USD | 571664.95% |
| Medite Cancer Diagnostics, Inc. | 4.9 Million USD | -380310.026% |
| Paradigm Medical Industries, Inc. | 2.16 Million USD | -862804.718% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | -43.3 Thousand USD | 43081570.534% |
| Reflect Scientific, Inc. | -1.03 Million USD | 1802077.578% |
| SmileDirectClub, Inc. | 778.67 Million USD | -2295.859% |
| Sector 10, Inc. | 163 Thousand USD | -11445298.773% |
| Shandong Weigao Group Medical Polymer Company Limited | -417.55 Million USD | 4567.922% |
| SheerVision, Inc. | 57.34 Thousand USD | -32530545.696% |
| United Health Products, Inc. | 660.56 Thousand USD | -2824131.836% |
| Vasamed, Inc. | 22.12 Thousand USD | -84332238.848% |
| Wearable Health Solutions, Inc. | 2.63 Million USD | -708924.98% |
| Yubo International Biotech Limited | 772.27 Thousand USD | -2415607.277% |